DR. VISHWARAJ C.R.

DR. KAVITHA S., DR. RENGARAJ VENKATESH

Abstract

Aim: To determine the safety and drug concentration levels of topical Latanoprost at the end of 4 and 6 weeks

Methods: Latanoprost of 4 companies were selected whose baseline concentration and contamination levels were analysed. Total of 50 patients were included in the study. Patients were randomized into 2 groups of 4weeks (Group A) and 6weeks follow up (Group B). They were given eyedrops of the company of same batch and were reviewed back after 4 or 6 weeks as per randomization. Drug concentration and contamination levels were analysed.

Results : A total of 25 patients were included in both groups.23 patients completed follow up in group A and 22 in group B. There was no significant difference in the drug concentration levels (P 0.324), contamination levels (P 0.759). There was no difference between different brands (P 0.356).

Conclusion: Latanoprost is safe and effective to use in patients till 6 weeks of follow up. Will help to reduce the economic burden on the patient